Abstract:Mitochondrial drug delivery has attracted increasing attention in various mitochondrial dysfunction-associated disorders such as cancer owing to the important role of energy production. Herein, we report a lysosomal pH-activated mitochondrial-targeting polymer nanoparticle to overcome drug resistance by a synergy between mitochondrial delivery of doxorubicin (DOX, an anticancer drug) and erlotinib-mediated inhibition of drug efflux. The obtained nanoparticles, DE-NPs could maintain negative charge and have long blood circulation while undergoing charge reversal at lysosomal pH after internalization by cancer cells. Thereafter, the acidity-activated polycationic and hydrophobic polypeptide domains boost lysosomal escape and mitochondrial-targeting drug delivery, leading to mitochondrial dysfunction, ATP suppression, and cell apoptosis. Moreover, the suppressed ATP supply and erlotinib enabled dual inhibition of drug efflux by DOX-resistant MCF-7/ADR cells, leading to significantly augmented intracellular DOX accumulation and a synergistic anticancer effect with a 17-fold decrease of IC50 relative to DOX. In vivo antitumor study demonstrates that DE-NPs efficiently suppressed the tumor burden in MCF-7/ADR tumor-bearing mice and led to negligible toxicity. This work establishes that a combination of mitochondrial drug delivery and drug efflux inhibition could be a promising strategy for combating multidrug resistance.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c03196?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c03196</a>.Synthetic scheme of PKCF; 1H NMR and FTIR spectra of polymers; DLS and zeta potentials of PKCF and D-NPs; cytotoxicity of PKCF NPs; cytotoxicity of Erlo and NPs against MCF-7 cells; cellular uptake of different formulations; cell cycle analysis; and H&E staining images of organs after treatment (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c03196/suppl_file/am1c03196_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Mitochondrial temperature-responsive drug delivery reverses drug resistance in lung cancer

Tumor-Penetrating and Mitochondria-Targeted Drug Delivery Overcomes Doxorubicin Resistance in Lung Cancer

Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy

Hypoxia-ameliorated photothermal manganese dioxide nanoplatform for reversing doxorubicin resistance

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Mitochondrial Targeted Doxorubicin Derivatives Delivered by ROS-responsive Nanocarriers to Breast Tumor for Overcoming of Multidrug Resistance.

Overcoming multidrug-resistant lung cancer by mitochondrial-associated ATP inhibition using nanodrugs

Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance

Mitochondria-targeted Vitamin E Succinate Delivery for Reversal of Multidrug Resistance

The Use of Mitochondrial Targeting Resveratrol Liposomes Modified with a Dequalinium Polyethylene Glycol-Distearoylphosphatidyl Ethanolamine Conjugate to Induce Apoptosis in Resistant Lung Cancer Cells

Targeting Therapy with Mitosomal Daunorubicin Plus Amlodipine Has the Potential to Circumvent Intrinsic Resistant Breast Cancer

Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer

Reversing Chemotherapy Resistance by a Synergy between Lysosomal pH-Activated Mitochondrial Drug Delivery and Erlotinib-Mediated Drug Efflux Inhibition

Mitochondria-Responsive Drug Release along with Heat Shock Mediated by Multifunctional Glycolipid Micelles for Precise Cancer Chemo-Phototherapy.

Dual Aptamer Modified Dendrigraft Poly-L-lysine Nanoparticles for Overcoming Multi-Drug Resistance Through Mitochondrial Targeting.

Hematoporphyrin and Doxorubicin Co-Loaded Nanomicelles for the Reversal of Drug Resistance in Human Breast Cancer Cells by Combining Sonodynamic Therapy and Chemotherapy

Mitochondrial Targeting Topotecan-Loaded Liposomes for Treating Drug-Resistant Breast Cancer and Inhibiting Invasive Metastases of Melanoma.

Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance

Co-delivery of metformin enhances the anti-multidrug resistant tumor effect of doxorubicin by improving hypoxic tumor microenvironment.

Mitochondria-targeting polydopamine-coated nanodrugs for effective photothermal- and chemo-synergistic therapies against lung cancer

A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia